ASHG supports policies that enable a productive and safe working environment for all scientific professionals. The Society is committed to promoting a harassment-free workplace for geneticists, and believes that science can only achieve its goals when we are able to fully engage the minds, talent, and perspectives of all who wish to participate. Related: Letter... Read More
Protections against genetic discrimination advance genetics research and the clinical use of genetics, as well as ensure the ethical use of genetic data. Ten years after the passage of the Genetic Information Nondiscrimination Act (GINA), ASHG remains a staunch advocate for GINA’s strong implementation and for other laws that enhance protections for the public. Related:... Read More
For Immediate Release Monday, November 26, 2018 1:30 p.m. U.S. Pacific Time Media Contact: Nalini Padmanabhan 301.634.7346 press@ashg.org Report from China, if Confirmed, Would Be at Odds with Field Consensus that Germline Editing is Not Ready for Human Use ROCKVILLE, Md. – Given this morning’s reports of infants possibly born in China whose genomes were... Read More
In 2018, the U.S. Food and Drug Administration (FDA) invited comments on its intention to exempt a list of class II devices from premarket notification requirements, including tests assessing genetic health risks. ASHG responded to this request for comment by outlining its support for regulation that brings scientifically valid, evidence-based tests to market, and expressing... Read More
In 2017, ASHG and 10 international organizations published a position statement on human germline genome editing in The American Journal of Human Genetics. The statement recommended against genome editing culminating in human pregnancy, supported publicly funded in vitro research into its potential clinical applications, and outlined scientific and societal steps necessary before implementation of such... Read More